-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Vericel (NASDAQ:VCEL) Versus Allena Pharmaceuticals (NASDAQ:ALNAQ) Financial Analysis
Vericel (NASDAQ:VCEL) Versus Allena Pharmaceuticals (NASDAQ:ALNAQ) Financial Analysis
Vericel (NASDAQ:VCEL – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
Profitability
This table compares Vericel and Allena Pharmaceuticals' net margins, return on equity and return on assets.
Get Vericel alerts:Net Margins | Return on Equity | Return on Assets | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
Risk and Volatility
Vericel has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Institutional & Insider Ownership
7.3% of Allena Pharmaceuticals shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 3.7% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.Valuation & Earnings
This table compares Vericel and Allena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vericel | $156.18 million | 7.19 | -$7.47 million | ($0.39) | -61.03 |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
Vericel has higher revenue and earnings than Allena Pharmaceuticals.
Analyst Ratings
This is a summary of recent recommendations and price targets for Vericel and Allena Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Vericel presently has a consensus price target of $37.40, suggesting a potential upside of 57.14%. Given Vericel's higher possible upside, equities research analysts clearly believe Vericel is more favorable than Allena Pharmaceuticals.
Summary
Vericel beats Allena Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About Vericel
(Get Rating)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
Vericel (NASDAQ:VCEL – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
威瑞塞尔(纳斯达克:VCEL-GET评级)和艾琳娜制药(纳斯达克:ALNAQ-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据这两家公司的收益、机构持股、股息、分析师建议、盈利能力、估值和风险等方面的实力进行比较。
Profitability
盈利能力
This table compares Vericel and Allena Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了Vericel和Allena制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena Pharmaceuticals | N/A | -287.46% | -146.58% |
净利润率 | 股本回报率 | 资产回报率 | |
Vericel | -11.36% | -10.48% | -7.45% |
Allena制药公司 | 不适用 | -287.46% | -146.58% |
Risk and Volatility
风险和波动性
Vericel has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Vericel的贝塔系数为1.99,这表明其股价的波动性比标准普尔500指数高出99%。相比之下,Allena PharmPharmticals的贝塔系数为1.36,这表明其股价的波动性比标准普尔500指数高36%。
Institutional & Insider Ownership
机构与内部人持股
Valuation & Earnings
估值与收益
This table compares Vericel and Allena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
该表格比较了Vericel和Allena PharmPharmticals的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Vericel | $156.18 million | 7.19 | -$7.47 million | ($0.39) | -61.03 |
Allena Pharmaceuticals | N/A | N/A | -$48.66 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Vericel | 1.5618亿美元 | 7.19 | -747万美元 | ($0.39) | -61.03 |
Allena制药公司 | 不适用 | 不适用 | -4,866万元 | 不适用 | 不适用 |
Vericel has higher revenue and earnings than Allena Pharmaceuticals.
Vericel的收入和收益高于Allena制药公司。
Analyst Ratings
分析师评级
This is a summary of recent recommendations and price targets for Vericel and Allena Pharmaceuticals, as provided by MarketBeat.
这是MarketBeat提供的Vericel和Allena制药公司最近的建议和目标价摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Vericel | 0 | 2 | 3 | 0 | 2.60 |
Allena制药公司 | 0 | 0 | 0 | 0 | 不适用 |
Vericel presently has a consensus price target of $37.40, suggesting a potential upside of 57.14%. Given Vericel's higher possible upside, equities research analysts clearly believe Vericel is more favorable than Allena Pharmaceuticals.
Vericel目前的共识目标价为37.40美元,这意味着潜在的上行空间为57.14%。考虑到Vericel更有可能的上行空间,股票研究分析师显然认为Vericel比Allena PharmPharmticals更有利。
Summary
摘要
Vericel beats Allena Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
Vericel在两只股票比较的10个因素中有8个击败了Allena PharmPharmticals。
About Vericel
关于Vericel
(Get Rating)
(获取评级)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel公司是一家商业阶段的生物制药公司,在美国从事运动医学和严重烧伤护理市场的细胞疗法的研究、开发、制造和分销。该公司销售自体细胞治疗产品,包括用于修复有症状的膝部单个或多个全层软骨缺陷的自体细胞化支架产品Maci,以及用于治疗成人和儿童深真皮或全面烧伤患者的永久性皮肤置换人道主义使用设备Epicel。其预批准阶段的产品是NexoBrid,这是一种注册阶段的生物孤儿产品,用于治疗成人深度部分和/或全层热烧伤的焦痂去除。该公司前身为阿斯特罗姆生物科学公司。Vericel公司成立于1989年,总部设在马萨诸塞州剑桥市。
About Allena Pharmaceuticals
关于Allena制药公司
(Get Rating)
(获取评级)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Allena制药公司是一家生物制药公司,在美国发现、开发和商业化口服酶疗法,用于治疗罕见和严重的代谢以及肾脏疾病患者。它的主要候选产品是ALLN-346,这是一种新型的尿酸降解酶,适用于晚期慢性肾脏疾病中的高尿酸血症和痛风患者。该公司成立于2011年,总部设在马萨诸塞州牛顿市。2022年9月2日,Allena制药公司根据破产法第11章向美国特拉华州地区破产法院提交了自愿重组请愿书。
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vericel Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vericel和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧